Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma: An immunohistochemical study

Cancer

Volumn 78, Issue 3, 1996, Pages 433-440

  Kristensen, Gunnar B ^a   Holm, Ruth ^a   Abeler, Vera M ^a   Tropé, Claes G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

c erbB 2; Cathepsin D; EGFR; prognosis; squamous cell carcinoma; uterine cervix

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; RADICAL HYSTERECTOMY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CATHEPSIN D; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 0029954643     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K     Document Type: Article

References (36)

1. Johnson D, Cox R, Billingham G, Ung N, Martinez A. Survival, prognostic factors and relapse patterns in uterine cervical carcinoma. Am J Clin Oncol 1983;6:407-15.
2. Rutledge FN, Mitchell MF, Munsell M, Bass S, McGuffee V, Atkinson EN. Youth as a prognostic factor in carcinoma of the cervix: a matched analysis. Gynecol Oncol 1992;44:123-30.
3. Stehman FB, Bundy BN, Disaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy: a multivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991;67:2776-85.
4. Alvarez RD, Potter ME, Soong SE, Gay FL, Hatch KD, Partridge EE, et al. Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients. Gynecol Oncol 1991;43:108-12.
5. Fuller AF, Elliot N, Kosloff C, Hoskins WJ, Lewis JL. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 1989;33:34-9.
6. Friedell G, Steiner G, Kistner R. Prognostic value of blood-vessel invasion in cervical cancer. Obstet Gynecol 1967; 29:855-7.
7. Stendahl U, Willén H. Willén R. Classification and grading of invasive squamous cell carcinoma of the uterine cervix. Acta Radiol Oncol 1979;18:481-96.
8. He C, Wilhelm SM, Pentland AP, Manner BL, Grant GA, Eisen AZ, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci 1989;86:2632-6.
9. Rochefort H. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990;16:3-13.
10. Reid WA, Valler MJ, Kay J. Immunolocalization of cathepsin D in normal and neoplastic human tissues. J Clin Pathol 1986;39:1323-30.
11. Spyratos F, Maudelonde T, Brouillet JP, Brunet M, Defrenne A, Andrieu C, et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989;2:1115-8.
12. r 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989;49:6008-14.
13. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Eng J Med 1990;322:297-303.
14. Granata G, Coradini D, Cappelletti V, DiFronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 1991;27:970-2.
15. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993;11:36-43.
16. Têtu B, Brisson J, Côté C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin D expression in node positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993;55:429-35.
17. Scambia G, Panici PB, Ferrandina G, Salerno G, D'Agostino G, Distefano M, et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 1994;30A:935-40.
18. Nazeer T, Malfetano JH, Rosano TG, Ross JR. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. J Clin Pathol 1992; 97:764-9.
19. Scambia G, Panici PB, Ferrandina G, Distefano M, Romanini ME, Sica G, et al. Significance of cathepsin D expression in uterine tumors. Eur J Cancer 1995;31A:1449-54.
20. Mitchell KM, Hale RJ, Buckley CH, Fox H, Smith D. Cathepsin D expression in cervical carcinoma and its prognostic significance. Virchows Arch A Pathol Anat Histopathol 1993;422:357-60.
21. Miyazawa K. Role of epidermal growth factor in obstetrics and gynecology. Obstet Gynecol 1992;79:1032-40.
22. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 1994;73:370-6.
23. Pfeiffer D, Stellwag B, Pfeiffer A, Borlinghaus P, Meier W, Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1989;33:146-50.
24. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993;46:149-53.
25. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
26. r tumour antigen. Nature 1984;312:513-5.
27. Mansour EG, Ravdin PM, Dressier L. Prognostic factors in early breast carcinoma. Cancer 1994;74:381-400.
28. Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, et al. Long-term survival in breast cancer related to over-expression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991;163:105-10.
29. Hale RJ, Buckley CH, Fox H, Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992;45:594-6.
30. Poulsen H, Taylor C. Histological typing of female genital tract tumors, No 13. Geneva: World Health Organization, 1975.
31. Hsu S-M, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981; 75:734-8.
32. Cattoretti G, Becker HG, Key G, Duchrow M, Schluter C, Galle J. Monoclonal antibodies against recombinants part of Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
34. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC. Expression of epidermal growth factor receptor and HER-2/Neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 1990;76:381-7.
35. Hayashi Y, Hachisuga T, Iwasaka T, Fukuda K, Okuma Y, Yokoyama M, et al. Expression of ras oncogene product and EGFR receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol 1991;40:147-51.
36. Dargent D, Brun JL, Roy M, Mathevet P, Remy I. La trachélectomie élargie (T.E.) Une alternative à l'hystérectomie radicale dans le traitement des cancers infiltrants développés sur la face externe du col utérin. JOBGYN 1994; 2:285-92.